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Objective: Measurements of oxidative stress biomarkers in patients with heart failure (HF) have yielded
controversial results. This study aimed at testing the hypothesis that circulating levels of the lipid
peroxidation product 4-hydroxynonenal bound to thiol proteins (4HNE-P) are strongly associated with
those of its potential precursors, namely n-6 polyunsaturated fatty acids (PUFA).
Methods and results: Circulating levels of 4HNE-P were evaluated by gas chromatography-mass spectro-
metry in 71 control subjects and 61 ambulatory symptomatic HF patients along with various other
clinically- and biochemically-relevant parameters, including other oxidative stress markers, and total
levels of fatty acids from all classes, which reﬂect both free and bound to cholesterol, phospholipids and
triglycerides. All HF patients had severe systolic functional impairment despite receiving optimal
evidence-based therapies. Compared to controls, HF patients displayed markedly lower circulating levels
of HDL- and LDL-cholesterol, which are major PUFA carriers, as well as of PUFA of the n-6 series,
speciﬁcally linoleic acid (LA; P¼0.001). Circulating 4HNE-P in HF patients was similar to controls, albeit
multiple regression analysis revealed that LA was the only factor that was signiﬁcantly associated with
circulating 4HNE-P in the entire population (R2¼0.086; P¼0.02). In HF patients only, 4HNE-P was even
more strongly associated with LA (P¼0.003) and HDL-cholesterol (po0.0002). Our results demonstrate
that 4HNE-P levels, expressed relative to HDL-cholesterol, increase as HDL-cholesterol plasma levels
decrease in the HF group only.
Conclusion: Results from this study emphasize the importance of considering changes in lipids and
lipoproteins in the interpretation of measurements of lipid peroxidation products. Further studies appear
warranted to explore the possibility that HDL-cholesterol particles may be a carrier of 4HNE adducts.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.
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Introduction
While considerable evidence supports the role of oxidative stress in
the development and progression of chronic diseases such as heart
failure (HF) [1–4], clinical trials with natural antioxidant interventions
conducted in the last two decades have yielded controversial results
[5–9]. However, until 2000, the few clinical studies that documented
circulating biomarkers of oxidative stress predominantly measured the
plasma level of malondialdehyde (MDA) using the highly criticized
thiobarbituric acid-reactive substances (TBARS) method without chro-
matographic separation [3,10–13]. More recently, urinary and plasma
isoprostanes, which arise from the peroxidation of the n-6 polyunsa-
turated fatty acid (PUFA) arachidonic acid (AA), have been advocated
for the in vivo assessment of oxidative stress status for human studies
[14–16]. However, it appears unlikely that the measurement of a single
biomarker will provide a comprehensive picture of the various
oxidative stress-related events that may contribute to progression of
cardiovascular diseases [17].
Another peroxidation product of the n-6 PUFAs AA and linoleic
acid (LA) that has generated considerable research interest for its
potential as a biomarker of oxidative stress is 4-hydroxynonenal
(4HNE) [18]. This aldehyde readily binds covalently to nucleophilic
residues of proteins, peptides, phospholipids, and nucleic acids
and thereby exhibits cytotoxic effects. 4HNE can also modulate
signaling pathways involved in cell proliferation, ﬁbrosis, apopto-
sis and inﬂammation, which are all hallmarks of cardiovascular
diseases, especially HF [19–21]. Interestingly, Nakamura et al.
showed that the myocardial levels of protein-bound 4HNE were
decreased after treatment with carvedilol in patients with HF [22],
and were also correlated with left ventricular dilatation and
systolic dysfunction in patients with hypertrophic cardiomyopathy
[23]. Recently, we developed and validated a method using gas
chromatography-mass spectrometry to quantify, with precision,
blood levels of total protein-bound 4HNE thioether adducts
(4HNE-P) [24]. Using this method, we reported a higher accumu-
lation of blood 4HNE-P in spontaneously hypertensive rats than in
normal rats, which correlated positively with left ventricular
diastolic dysfunction [24,25], and in hypercholesterolemic rabbits
[26]. These ﬁndings support a role for this biomarker in the
pathophysiological events linked to heart disease progression,
although it has not yet been documented in humans.
Measurements of oxidative stress in cohorts of patients with HF
have, however, yielded controversial results, with some studies
[13,27,28] reporting an increase in these biomarkers. This discrepancy
has been attributed in part to current drug therapies [29] that include
β-blockers [22,28,30], renin-angiotensin system (RAS) inhibitor, and
statins [31,32], which exert indirect antioxidant effects through
regulation of free radical-producing processes or of antioxidant
defenses. However, since commonly measured biomarkers of oxida-
tive stress are predominantly lipid peroxidation products, one other
factor that may contribute to this discrepancy is the circulating level of
PUFAs, which are the precursors of these biomarkers and are affected
by disease [33] and/or by pharmacological treatment such as statins
[34]. In their recent review, Halliwell and Lee [35] recognized that this
issue should be further explored.
Therefore, in this study we tested the hypothesis that circulat-
ing levels of the lipid peroxidation product 4-hydroxynonenal
bound to proteins (4HNE-P) are strongly associated with those of
its potential precursors. Hence, we documented circulating levels
of (i) biomarkers of oxidative stress, including 4HNE-P but also the
commonly assessed malondialdehyde, as well as (ii) total fatty
acids, which include all classes of fatty acids and reﬂect both free
and bound fatty acids, either to albumin or esteriﬁed to cholesterol
or as triglycerides and phospholipids in lipoproteins, in a popula-
tion of 61 symptomatic ambulatory HF patients receiving
evidence-based therapies and 71 control subjects.
Patients and methods
Study population and design
This study involved a total of 132 subjects. A group of 61
symptomatic patients followed at the Heart Failure Clinic of the
Montreal Heart Institute (HFC-MHI) who were older than 45 years
and had a left ventricular ejection fraction r40%, as determined
by echocardiography, was studied. The HFC-MHI is a multidisci-
plinary specialized outpatient disease management program.
Symptomatic HF patients are referred to the clinic by a MHI
cardiologist after an emergency department visit or a hospital
admission for documented HF. Thus, this clinic is restricted to
patients at high risk of decompensation, needing a close medical
follow-up [36]. For the purpose of this analysis, patients with
recent (o3 months) cardiac surgery were excluded. We also
studied 71 control subjects who were older than 45 years and
free of signiﬁcant cardiovascular disease or risk factors such as
diabetes mellitus, untreated dyslipidemia or hypertension, severe
obesity (Body mass index Z32 kg/m2) or cigarette smoking
(Z25/day). Complete medical assessment, including history and
physical examination, was performed and a 20-ml blood sample
was drawn from an antecubital vein after overnight fast. Blood and
plasma samples were collected in EDTA tube and immediately
frozen in liquid nitrogen and stored at 80 1C until assayed. The
investigation conformed to the principles outlined in the Declara-
tion of Helsinki. The study protocol was approved by the MHI
research ethics committee and all subjects gave written informed
consent.
Biochemical determinations and calculations
The following assays on plasma samples were performed
according to the manufacturer0s instructions: glucose, creatinine,
blood urea, HDL-cholesterol and triglycerides were determined by
spectrophotometric methods, using respective reagent Flex on a
multianalyzer Dimension RxL Max (Dade Behring Diagnostics,
Marburg, Germany), N-terminal proB-type natriuretic peptide
(NT-proBNP) and troponin T were assessed by electrochemilumi-
nescence immunoassay on a Elecsys 2010 analyzer using Roche
assay kits (Roche Diagnostic, Mannheim, Germany), and C-reactive
protein (CRP) was quantiﬁed using the Dade Behring N High
Sensitivity assay (Dade Behring Diagnostics, Marburg, Germany)
on the BN ProSpec Nephelometer. Insulin was quantiﬁed by a
double-antibody radioimmunoassay (Bi-Ins-IRMA kit, CIS Bio
International, Gif-sur-Yvette, France). ELISA kits were used to
assess levels of Tumor Necrosis Factor-alpha (TNF-α) (R&D Sys-
tems, Minneapolis, USA) and myeloperoxidase (MPO) (Oxis Inter-
national Inc., Foster City, USA). Levels of reduced (GSH) and
oxidized (GSSG) glutathione were determined in 200 ml of whole
blood by capillary electrophoresis according to Serru et al. [37].
The amount of free MDA formed during the TBARS reaction was
determined by HPLC, and the plasma fatty acid composition was
assessed as previously described with some minor modiﬁcations
[38,39]. The estimated glomerular ﬁltration rate (eGFR) and the
homeostatic model assessment of insulin resistance (HOMA-IR)
were calculated by the Cockcroft and Gault [40] and Matthews [41]
formulas, respectively. The cholesterol ratio was calculated from
the total-cholesterol value divided by the HDL-cholesterol value.
Statistical analysis
Patient characteristics are expressed as mean7SD, median
[minmax], or frequencies and percentages when appropriate.
Because of signiﬁcant differences in age and gender between the
control and HF patients, comparisons between these two groups of
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subjects for clinical and biochemical characteristics were con-
ducted using an analysis of covariance (ANCOVA) adjusting for age
and sex as covariates. For parameters exhibiting a severely skewed
distribution, a logarithmic transformation was used. To test for
NYHA classes and type 2 diabetes among the HF group, categorical
variables were analyzed using Pearson chi-square tests and con-
tinuous variables with t-tests or Mann–Whitney–Wilcoxon tests
(according to the distribution of the variable). Supplementary
analyses were conducted for (i) primary outcomes measures,
namely the oxidative stress marker 4HNE-P and its potential
precursors the n-6 PUFA LA, as well as for the commonly assessed
oxidative stress marker MDA. For LA, covariance analysis was
conducted for further adjusting values to plasma levels of the
various cholesterol classes (total, LDL- and HDL-cholesterol) as
covariates, in addition to age and gender. For 4HNE-P, Pearson
correlation analyses were conducted to test its association with its
potential precursors. We assessed also risk factors and parameters
associated with its circulating levels using multiple linear regres-
sion analysis. This analysis was performed (i) in the entire
population and subsequently (ii) in HF patients only using the
following risk factors and parameters, which were selected for
their high clinical and biochemical relevance: (i) group, age, body
mass index, sex, log NT-proBNP, malondialdehyde (MDA),
reduced-to-oxidized glutathione ratio, myeloperoxidase, lympho-
cytes, tumor necrosis factor-α, C-reactive protein, HDL-cholesterol,
LDL-cholesterol, triglycerides, insulin, glucose, uric acid, estimated
glomerular ﬁltration rate, total bilirubin, alkaline phosphatase,
linoleic acid and arachidonic acid, and (ii) all parameters listed
in (i) except group, plus systolic pressure, NYHA class, left
ventricular ejection fraction, etiology, non-insulin dependent dia-
betes mellitus, hypertension, myocardial infarction, medication
(β-blocker, RAS inhibitor, calcium channel inhibitor, chronic nitrate,
acute nitrate, amiodarone, digoxin, warfarin, salicylates, diuretics,
hypolipidemic agents, hypoglycemic agents, allopurinol). For MDA,
we have also conducted a multiple linear regression analysis in HF
patients only using the same risk factors and parameters listed
above for 4HNE-P, except that MDA was replaced with 4HNE-P. All
these parameters were entered into a stepwise selection proce-
dure with a 0.1 signiﬁcance level for staying in the model.
Parameters with a P-value between 0.05 and 0.1 were kept in
the model to indicate potential trends. A P-value o0.05 was
considered statistically signiﬁcant. Statistical analyses were per-
formed using SAS version 9.1 or higher (Cary, NC, USA).
Results
Clinical and biochemical characteristics of HF patients and
controls, including medications used, are summarized in Tables 1
and 2; these tables include parameters routinely assessed in
clinical laboratories. Circulating levels of lipid peroxidation mar-
kers and of their potential n-6 PUFA precursors, as well as other
fatty acids can be found in Tables 3 and 4, respectively. Because the
HF patient cohort was slightly older and had a greater proportion
of men than controls, all tables report only statistical differences
which remained signiﬁcant after adjustment for age- and gender-
differences.
Clinical and biochemical characteristics of the study population
Our population of HF patients had a markedly depressed left
ventricular ejection fraction with a mean of 26.377.1% and
moderate to severe functional impairment, being mostly in New
York Heart Association (NYHA) classes II (54%) and III (44%). These
patients were mostly of ischemic etiology (66%) and the vast
majority of them presented 2 or more comorbidities, such as type
2 diabetes (48%) and hypertension (49%). Finally, as per guidelines
recommendation, HF patients received multiple medications com-
pared to controls (7.472.0 vs. 0.871.2 medications/subject,
Po0.0001), which included diuretics (97%), RAS inhibitors (85%),
β-blockers (79%), lipid-lowering agents (75%), warfarin (48%) and
salicylates (65%).
With respect to circulating parameters routinely assessed in the
clinical laboratory, as expected, HF patients exhibited markedly
increased plasma levels of NT-ProBNP, uric acid, urea and creatine;
some degree of renal dysfunction was evidenced by a lower eGFR.
While 16% of them had an elevated plasma troponin T level
(Z0.03 μg/L), their plasma levels of inﬂammation markers namely
TNF-α (50%), CRP (71%) and MPO (41%), were also signiﬁcantly higher.
At the metabolic levels, HF patients displayed markedly lower
levels of HDL-cholesterol (38%) and LDL-cholesterol (23%), but a
greater [total cholesterol]/[HDL-cholesterol] ratio (21%), and higher
levels of triglycerides (51%). They also showed signiﬁcantly higher
plasma levels of glucose (55%) and insulin (56%), as well as HOMA-IR
scores (135%).
Table 1
Clinical characteristics of heart failure (HF) patients and controls.
Parameters Control HF
N 71 61
Subjects characteristics
Gender (male, %) 37 (52%) 47 (77%)nnn
Age (years) 5979 67710nnnn
Body mass index (kg/m2) 25.972.9 26.974.3
Clinical parameters
Left ventricular ejection fraction (%) n.d. 26.377.1
NYHA Classa
I n.a. 1 (2%)
II 33 (54%)
III 27 (44%)
Systolic blood pressure (mmHg) 119713 106719nnnn
Diastolic blood pressure (mmHg) 7378 5879nnnn
Heart rate (bpm) 6877 68710
Medical history (etiology/comorbidities)
Ischemic etiology 0 39 (64%)nnnn
Dyslipidemia 19 (27%) 55 (90%)nnnn
Hypertension 0 30 (49%)nnnn
Type 2 diabetes 0 29 (48%)nnnn
History of myocardial infarction 0 33 (54%)nnnn
Medications
RAS inhibitor 7 (10%) 52 (85%)nnnn
β-blocker 3 (4%) 48 (79%)nnnn
Digoxin 0 42 (69%)nnnn
Lipid-lowering agentsb 17 (24%) 46 (75%)nnnn
Diureticsc 5 (7%) 59 (97%)nnnn
Aspirin 1 (1%) 29 (48%)nnnn
Salicylates 9 (13%) 39 (65%)nnnn
Chronic nitrate 0 18 (30%)nnnn
Spironolactone 0 42 (62%)nnnn
Acute nitrate 0 22 (36%)nnnn
Allopurinol 1 (1%) 19 (31%)nnnn
Amiodarone 0 17 (28%)nnnn
Warfarin 1 (1%) 29 (48%)nnnn
Calcium channel antagonists 3 (4%) 3 (5%)
Hypoglycemic agents 0 21 (35%)nnnn
Data are means7SD, median [minmax] or number of patients (percentage).
NYHA, New York Heart Association, n.a., not applicable, n.d., not determined, RAS,
renin-angiotensin system.
a This classiﬁcation applies for HF patients only.
b Lipid-lowering agents include statins and ﬁbrates.
c Diuretics include loop diuretic, thiazides and potassium sparing diuretic.
nPo0.05, nnPo0.01, nnnPo0.001 and nnnnPo0.0001: HF vs. controls, using
ANCOVA adjusting for age and sex as covariates.
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It is noteworthy that none of the reported parameters in
Tables 1 and 2 were found to differ signiﬁcantly between NYHA
classes I–II vs. III of HF patients (data not shown) and only a few of
them differed signiﬁcantly between HF patients with or without
type 2 diabetes (diastolic blood pressure: po0.01, glucose
po0.0001 and HOMA-IR po0.03).
Circulating levels of lipid peroxidation markers and their potential
fatty acid precursors
HF patients depicted signiﬁcantly elevated levels of blood GSH-
to-GSSG ratio (55%; Table 3). This higher ratio was due to a
signiﬁcantly decreased blood level of GSSG (22%), while those of
GSH and total glutathione were similar in both groups. Similarly,
compared to controls, HF patients displayed similar circulating
levels of MDA, a commonly assessed lipid peroxidation marker, as
well 4HNE-P (Table 3).
With regards to the plasma level of total fatty acids, which
reﬂect both free and bound fatty acids, either to albumin or
esteriﬁed to cholesterol or as triglycerides and phospholipids in
lipoproteins, this did not differ between groups. However, con-
curring with literature data [33], HF displayed a markedly altered
fatty acid proﬁle compared to controls (Table 4), including
decreased level of potential 4HNE-P precursors the n-6 PUFA,
speciﬁcally LA (by 15%) that represents 75% of all n-6 PUFA,
while that of arachidonic acid was unchanged. There were also
changes in the plasma levels of other fatty acid classes, namely a
decrease in the level of n-3 PUFAs, with an increased n-6/n-3 PUFA
ratio (11.773.4 vs. 9.173.0, Po0.0001), while that of mono-
unsaturated fatty acids (MUFA) was higher and saturated fatty
acids remained unchanged. In the n-3 series, the levels of both EPA
and DHA were lower by almost 50%. It is noteworthy that, despite
their lower levels of n-6 and n-3 PUFAs, HF patients do not depict
essential fatty acid deﬁciency as a result of undernutrition or fat
malabsorption, since the ratio (20:3n-9/20:4n-6) and (C16:1n-
7/18:2n-6) remained within the normal range [42].
Circulating levels of 4HNE-P, but not MDA, are associated to that of its
potential PUFA precursors
Additional statistical analyses, both univariate correlation Pear-
son analysis as well as multivariate regression analysis (Table 5),
which included both age and gender as variables, were conducted
in the entire population and revealed a strong association between
circulating 4HNE-P and its potential precursor LA. In fact, using
multiple regression analysis, LA was found to be the only
Table 3
Circulating levels of oxidative stress-related parameters in HF patients and controls.
Parameters Control HF
N 71 61
GSH (μM) 561.97154.9 555.67168.4
GSSG (μM) 42.9721.9 33.3722.2
GSH-to-GSSG ratio 15.777.7 24.3718.7nn
Malondialdehyde (μM) 9677313 11437473
4HNE-P (μM) 223797 2137113
Data are means7SD. GSH: reduced glutathione; GSSG: oxidized glutathione.
nnPo0.01: HF vs. controls, using ANCOVA adjusting for age and sex as
covariates.
Table 4
Total plasma fatty acid concentration in HF patients and controls.
Fatty acids/Concentration Control HF
lM lM
TOTAL 15,16972951 15,03075433
(A) PUFA 620271012 529871526nnnn
n-6 55187926 482671377nnn
C18:2n-6 (linoleic acid) 42267804 359271192nn
C18:3n-6 (gamma linolenic) 70.6728.1 69.9736.3
C20:3n-6 (dihomogamma acid) 203761 183767
C20:4n-6 (arachidonic acid) 976.27235.8 930.27267.0
n-3 6647238 4467194nnnn
C18:3n-3 (α-linolenic acid) 96.3732.4 97.0745.6
C20:5n-3 (EPA) 1587112 81.4745.2nnnn
C22:5n-3 (DPA) 67.4718.2 61.2728.2
C22:6n-3 (DHA) 3387123 2027109nnnn
(B) Mono-unsaturated fatty acids 380871039 451372006n
n-9 31697821 378871587nn
C18:1n-9 (oleic acid) 29247808 355671566n
C18:1n-9T (elaidic acid) 33.9716.5 45.6724.5n
C20:3n-9 (eicosatrienoic acid) 19.7710.1 26.1714.8n
C22:1n-9 (erucic acid) 51.7710.0 53.6717.1
C24:1n-9 (nervonic acid) 149738 126736n
n-7 6047241 6807431
C16:1n-7 (palmitoleic acid) 3617185 3997336
C18:1n-7 (vaccenic acid) 243763 2817108
Trans fatty acids 50.3719.9 64.4729.2nn
Saturated fatty acids 521471261 529172240
C12:0 (lauric acid) 19.8710.3 26.0721.5
C14:0 (myristic acid) 197795 1957123
C16:0 (palmitic acid) 38097973 393271867
C18:0 (stearic acid) 8907208 8947249
C20:0 (arachidic acid) 30.075.4 27.275.3n
C22:0 (behenic acid) 90.1719.8 67.2722.4nnnn
C24:0 (lignoceric acid) 67.7721.9 37.9715.8nnnn
Data are means7SD. PUFA, polyunsaturated fatty acid, EPA, eicosapentaenoic acid,
DPA, Docosapentaenoic acid, DHA, docosahexanaenoic acid.
nPo0.05, nnPo0.01, nnnPo0.001 and nnnnPo0.0001: HF vs. controls, using
ANCOVA adjusting for age and sex as covariates.
Table 2
Standard laboratory parameters assessed in HF patients and controls.
Parameters Control HF
N 71 61
NT-Pro-BNP (ng/L)a 57 2641nnnn
[12–559] [101–35,000]
Increased troponin T (Z0.03 mg/L) 0 11 (16%)
Creatinine (μM) 83718 1607119nnnn
eGFR (ml/min) 83.1721.0 51.7728nnnn
Blood urea (mM) 6.071.4 12.175.7nnnn
Uric acid (μM) 282777 4317139nnnn
Total bilirubin (μM) 10.6 74.9 11.977.3
C-reactive protein (μg/ml)a 2.0273.22 7.0879.27nnnn
Tumor necrosis factor-α (pg/ml) 1.1370.36 2.2670.85nnnn
Myeloperoxidase (ng/ml)a 16.976.7 28.8744.0nnn
Leukocytes (109/L) 5.8071.34 7.6571.98nnnn
Lymphocytes (109/L) 0.3070.08 0.2270.07nnnn
Hemoglobin (g/L) 142710 133716nnnn
Platelets (109/L) 240752 213767
Total cholesterol (mM) 5.1070.79 4.0771.09nnnn
HDL-Cholesterol (mM) 1.4570.43 0.9070.27nnnn
LDL-Cholesterol (mM) 3.1570.69 2.4270.92nnnn
Total cholesterol/HDL ratio 3.7370.93 4.7471.38nnn
Triglycerides (mM) 1.1170.53 1.6871.06nn
Glucose (mM) 4.6070.47 7.1272.51nnnn
Insulin (mU/L) 6.3372.86 9.8575.97nnn
HOMA-IR 26.7711.9 55.7735.1nnnn
Data are means7SD, median [minmax] or number of patients (percentage).
NT-ProBNP, N-terminal proB-type natriuretic peptide, eGFR, estimated glomerular
ﬁltration rate, HOMA-IR: homeostatic model assessment of insulin resistance,
calculated from Ref. [41].
a Parameters exhibiting a severely skewed distribution and for which a
logarithmic transformation was used.
nPo0.05, nnPo0.01, nnnPo0.001 and nnnnPo0.0001: HF vs. controls, using
ANCOVA adjusting for age and sex as covariates.
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parameter that was positively associated with 4HNE-P in the
entire population (β-coefﬁcient 0.0139, P¼0.0183).
Results from the univariate analysis conducted in the two
groups of subjects separately revealed, however, that only the HF
group showed a signiﬁcant association between 4HNE-P and LA
(Table 5). The relationship between 4HNE-P and LA for the two
groups is depicted in Fig. 1.
When multiple regression analyses were conducted in the HF
group only, LA remained strongly associated with 4HNE-P (Table 6).
The multiple regression analysis suggested, however, additional
factors that could explain variations in blood levels of 4HNE-P in
HF patients (R2¼0.5692) and the strongest association was found for
HDL-cholesterol (Po0.0002). Interestingly, 4HNE-P in HF patients
was found to be also associated positively with disease-related
parameters such as the NYHA class. The aforementioned associations
appear speciﬁc to 4HNE-P, since MDA, which is another product of
peroxidation of n-6 PUFA, was not found to be signiﬁcantly asso-
ciated with either LA or arachidonic acid in an univariate Pearson
correlation analysis (data not shown) nor in multiple regression
analysis conducted in the entire population neither in HF patients
using MDA as the dependent variable (Table 6). In fact, MDA showed
signiﬁcant positive associations with plasma glucose only, as well as
MPO and hypertension.
Further to results of our multiple regression analysis, supplemental
analyses were conducted in the entire population to explore the
relationship between LA and the speciﬁc cholesterol fractions, and
more speciﬁcally HDL-cholesterol. Using Pearson correlation tests, we
found a strong positive association between LA and each of the
cholesterol fraction (Po0.0001): total cholesterol (R¼0.771,
Po0.0001)4LDL-cholesterol (R¼0.674, Po0.0001)4HDL-choles-
terol (R¼0.276, P¼0.0013) (Fig. 2A). In addition, covariance analysis
was conducted using age, gender and the plasma levels of the various
cholesterol classes (total, LDL- and HDL-cholesterol) as covariates.
After adjustment, the difference between HF patients and controls was
no longer signiﬁcantly different for LA (3895797 vs. 3998790 μM;
p¼0.40; Fig. 2B), suggesting that the difference in plasma level of LA
between HF patients and controls is explained by that of cholesterol,
total, HDL- and LDL-cholesterol. The relationship between 4HNE-P and
HDL-cholesterol in HF patients and control subjects is depicted in
Fig. 3: HNE-P levels are expressed either as absolute values (Fig. 3A),
and as a molar ratio relative to HDL cholesterol, as an index of the
content of 4HNE-P per unit of HDL-cholesterol molecule (Fig. 3B).
Collectively, these results suggest that the HNE-P level expressed per
unit of HDL-cholesterol increases as the plasma level of HDL-
cholesterol decreases in the HF group.
Table 5
Blood level of 4-hydroxynonenal-protein thioether adducts (4HNE-P) and its association with that of its potential precursors in the
entire population of HF patients and control subjects.
HFþControl HF Control
Parameters R Coefﬁcient; P R Coefﬁcient; P R Coefﬁcient; P
Total n-6 PUFA R¼0.262; P¼0.003 R¼0.396; P¼0.002 R¼0,093; P¼0.483
Linoleic acid R¼0.252; P¼0.004 R¼0.366; P¼0.004 R¼0.106; P¼0.378
Arachidonic acid R¼0.119; P¼0.176 R¼0.316; P¼0.013 R¼0.058; P¼0.627
HDL-cholesterol R¼0.121; P¼0.166 R¼0.323; P¼0.011 R¼0.014; P¼0.909
LDL-cholesterol R¼0.087; P¼0.329 R¼0.222; P¼0.085 R¼0.112; P¼0.358
Triglycerides R¼0.099; P¼0.254 R¼0.128; P¼0.324 R¼0.162; P¼0.177
Results are Pearson coefﬁcient (R) and P values from correlation analysis between 4HNE-P and its potential precursors reported in
Tables 2 and 4. Correlations that are signiﬁcant are shown in bold.
Fig. 1. Relationship between circulating levels of 4-hydroxynonenal bound to
circulating thiol proteins (4HNE-P) and its precursor the n-6 polyunsaturated fatty
acid linoleic acid in control and heart failure (HF) subjects. The dotted lines show
the linear regression lines with 95% conﬁdence intervals for all subjects in the
control (C) and HF group. Control: Linoleic acid¼1.24HNE-Pþ3691, P¼0.38 (NS),
HF: Linoleic acid¼6.54HNE-Pþ2207, P¼0.004.
Table 6
Parameters associated with blood 4HNE-P and MDA levels in HF patients
(multiple regression analysis).
Parameters β Coefﬁcient P
4HNE-P (R2¼0.5692)
Lipid proﬁle-potential precursors
Linoleic acid 0.0184 0.0031
HDL-Cholesterol 102.4 0.0002
Disease-related parameters
NYHA 43.4 0.0015
History of myocardial infarction 35.5 0.0122
Various factors
Body mass index 4.11 0.0194
Total bilirubin 2,06 0.0268
Ratio GSH/GSSG 0.758 0.0462
Medication
RAS inhibitors 63.8 0.0034
Acute nitrate 31.7 0.0034
Hypoglycemic agents 29.1 0.0485
MDA (R2¼0.4074)
Disease-related parameters
History of myocardial infarction 244 0.0228
Risk factors
Hypertension 233 0.0286
Biochemical parameters
Glucose 48.2 0.0202
Alkaline phosphatase 2.57 0.0379
Myeloperoxidase 4.36 0.0005
Medication
Amiodarone 299 0.0151
Multivariate analysis was performed in HF patients only using risk factors and
parameters selected for their high clinical and biochemical relevance, which are
listed in the Material and Methods. A P-valueo0.05 was considered statistically
signiﬁcant.
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Discussion
In support of our initial working hypothesis, this study docu-
ments a signiﬁcant strong association between circulating levels of
4HNE-P and its potential precursors, particularly the n-6 PUFA LA
and HDL-cholesterol. Given that the levels of these precursors are
reduced signiﬁcantly in HF patients compared to controls, this
raises an important question about data interpretation of mea-
surements of absolute values for plasma levels of 4HNE-P, and
thereby emphasizes the importance of measuring changes in the
levels of 4HNE-P with its potential precursors.
In fact, our results highlight signiﬁcant positive associations
between circulating levels of 4HNE-P and LA, a n-6 PUFA, using
univariate correlation and multiple regression analyses in the
entire population. However, multiple regression analysis con-
ducted in the HF group only revealed a stronger association with
HDL-cholesterol than LA. Concurring with the notion that lipo-
proteins are the predominant PUFA carrier in plasma, plasma
levels of LA were strongly correlated with those of HDL-choles-
terol, and were no longer signiﬁcantly different between the
control and HF groups, when adjusted for the levels of total
cholesterol, HDL- and LDL-cholesterol. Hence, on this basis, sup-
plemental analyses were focused on the relationship between
4HNE-P and HDL-cholesterol.
Interestingly, these supplementary analyses demonstrate that
the level of 4HNE-P, expressed relative to that of HDL-cholesterol,
increases as the level of HDL-cholesterol decreases in the HF
population. This may appear surprising given that HDL-
cholesterol has been shown to exert a protective role against
cardiovascular disease through multiple mechanisms [43,44].
However, a number of studies have shown that HDL, and not
LDL, particles may well be the circulating lipoprotein that carries
the greatest oxidized lipid load, and emphasized the consequences
of oxidative damage to proteins comprised in HDL particles, which
would make them dysfunctional and thereby contribute to disease
outcome [45–50]. Consistent with this notion, Woodward et al.
recently reported a strong positive correlation between plasma
levels of the lipid peroxidation product F2-isoprostanes and HDL-
cholesterol in a cohort of coronary patients and control subjects,
although levels of F2-isoprostanes were not different between
groups [51]. Our ﬁnding of a positive association between HDL-
cholesterol and circulating levels of total protein-bound 4HNE in
HF patients in this study raise the possibility that this speciﬁc lipid
peroxidation product may contribute to protein modiﬁcation in
HDL particles.
Beyond HDL-cholesterol, our multiple regression analysis revealed
that circulating levels of 4HNE-P were also negatively associated with
the GSH-to-GSSG ratio [52,53], which was elevated in HF patients
suggesting an adaptive up-regulation of enzymes involved in glu-
tathione synthesis and recycling in response to the increased oxidative
stress in these patients. In support of this notion, abnormalities in GSH
Fig. 2. Relationship between circulating levels of linoleic acid and cholesterol fractions in the entire population. (A) Correlation between levels of linoleic acid (LA) and total
cholesterol, LDL- and LDL-cholesterol in the entire population. The dotted lines show the regression lines: (i) total cholesterol: R2¼0.595, Po0.0001, total
cholesterol¼0.79 LAþ1.52; (ii) LDL-cholesterol: R2¼0.455, Po0.0001, LDL-cholesterol¼0.567 LAþ0.583; and (iii) HDL: R2¼0.076, P¼0.001, HDL-
cholesterol¼0.120 LAþ0.726. (B) Circulating levels of LA adjusted for age, gender and lipoproteins variables assessed by ANCOVA. Values are means7SD.
Fig. 3. Relationship between 4HNE-P and HDL-cholesterol expressed in absolute values
or relative to HDL-cholesterol in heart failure (HF) and control (C) subjects. The lines in
Fig. 2A show the linear regression lines for each group: (i) HF: R2¼0.086, P¼0.016,
regression equation: HDL-cholesterol¼0.00144HNE-Pþ0.651, and (ii) controls:
R2¼0.0149, P¼0.768, regression equation: HDL-cholesterol¼0.000224HNE-
Pþ1.51.
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cycling were previously reported to be linked with increased lipid
peroxidation in HF patients [54]. It remains, however, unclear whether
circulating sulfhydryl groups represent the ﬁrst line of defense against
reactive species that can initiate lipid peroxidation in blood of HF
patients, which display high levels of MPO and leukocytes. Indeed, on
the one hand, the relative abundance of circulating 4HNE-P levels has
been shown to depend on their removal by phase II metabolic
pathways such as gluthathione-S-transferases [21]. On the other hand,
Frei et al. [55] showed that the formation of hydroperoxides from
plasma cholesterol and phospholipid esters in the presence of
activated leukocytes occurs following depletion of plasma ascorbate
(known to scavenge the MPO oxidant hypochlorous acid) even though
sulfhydryl groups are still present at high concentrations.
The participation of additional antioxidative mechanisms such
as heme oygenase (HO) or paraoxonase in HDL-cholesterol parti-
cles [56,57], cannot be excluded. While we did not directly assess
these mechanisms, indirect evidence supports a role for HO.
Indeed, our multiple regression analysis in HF patients only
revealed also a negative association between circulating levels of
4HNE-P and those of bilirubin. Interestingly, plasma bilirubin
levels of HF patients were not signiﬁcantly different from controls.
Bilirubin, which is the end product of heme catabolism, has been
shown to depict chain-breaking antioxidant properties [58] and to
inhibit peroxidation of lipids in lipoproteins [59]. HO catalyzes
heme oxidation and the induction of cardiac isoform (HO-1) under
pathophysiological stresses has also been linked to inhibition of
lipid peroxidation [60,61]. One potential source of non-protein-
bound heme – considered a particularly deleterious species – is
oxidation of hemoglobin released following erythrocyte lysis,
which can be induced by lipid peroxidation end-products such
as 4HNE [62] and constitutes a well known mechanism that
induces HO-1 [63]. Interestingly, in this regard, is our ﬁnding of
signiﬁcantly lower hemoglobin levels in our HF patient cohort vs.
controls.
Finally other factors identiﬁed by the multiple regression
analyses include the NYHA class. Two small studies reported a
link between NYHA classes and oxidative stress markers [27,64].
However, it should be noted that the characteristics of our HF
patient population, which is typical for a HF clinic, did not provide
adequate discrimination of the role of some clinically-relevant
parameters in the multiple regression analysis. Additional studies
are needed to substantiate this association using a larger HF and
control cohort, which would be randomized for age and gender.
Interestingly, in contrast to 4HNE-P, plasma levels of MDA did
not show any associations with LA or HDL-cholesterol or any other
lipid parameters. In our study, MDA levels were not signiﬁcantly
elevated in HF patients, a ﬁnding that concurs with that of Tingberg
et al. [29], but contrasts with other studies [13,27,65,66]. It is
noteworthy that while both 4HNE and MDA are lipid peroxidation
by-products, MDA can also be generated by cyclooxygenases in
thromboxane metabolism [67] and from free radical attack on
sialic acid and deoxyribose [68]. Thus, these two biomarkers may
reﬂect different pathogenic events linked to HF. This possibility is
supported by the results of supplemental statistical analyses
conducted in HF patients, which revealed that 4HNE-P and MDA
were associated with different disease-related parameters and
metabolites. Another factor that should also be considered is that
we assessed free MDA levels in plasma, while 4HNE-P reﬂects
4HNE bound to all circulating proteins, which may be albumin or
within lipoproteins, as it is suggested from by our correlation
an multiple regression analyses. Nevertheless, the relationship
depicted between 4HNE-P and its lipid precursors appears to be
speciﬁc to 4HNE-P, and not MDA. Further studies are needed,
however, to identify unambiguously circulating protein(s) that
bind 4HNE, as well as factors that could explain the reduction
in the circulating levels of lipoproteins as well as essential PUFAs,
which include the n-6 series, but also the n-3 series. In this
regard, other mass spectrometric methods combining enrichment
strategies with targeted analysis such as neutral loss scanning
should be used to enable detection and identiﬁcation of 4HNE-
modiﬁed proteins in complex biological matrices, including HDL
particles [18].
In conclusion, results from this study document a strong
association between the lipid peroxidation product 4HNE-P, but
not MDA, and its potential precursors the n-6 PUFA LA and HDL-
cholesterol, which is a major plasma PUFA carrier, in HF patients.
This relationship suggests that in relative term, the level of 4HNE-
P increases markedly as the level of HDL cholesterol decreases in
these patients. Results from this study emphasize the importance
of measuring the levels of these PUFA when assessing their lipid
peroxidation by-products such as 4HNE-P. Based on our ﬁndings, it
appears also warranted to test the possibility that 4HNE-P con-
tributes to oxidative stress-induced HDL protein modiﬁcation and
dysfunction in HF patients.
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